The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor

• Main Authors: Chen Y, Guo W, Fan J, Zhang X, Chen X, Luo P
• Format: Article
• Language: English
• Published: Dove Medical Press 2017-12-01
• Series: Cancer Management and Research
• Subjects: NSCLC; ALK; resistance; liquid biopsy; circulating tumor cells(CTCs); ctDNA; exosome
• Online Access: https://www.dovepress.com/the-applications-of-liquid-biopsy-in-resistance-surveillance-of-anapla-peer-reviewed-article-CMAR

Yating Chen,1,* Wenjie Guo,1,* Junsheng Fan,2,* Yuqing Chen,1 Xiaoli Zhang,1 Xin Chen,1 Peng Luo1 1Department of Respiratory, Zhujiang Hospital of Southern Medical University, Guangzhou, China; 2Department of Respiratory, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China *These authors contributed equally to this work Abstract: With the clinical promotion of precision medicine and individualized medical care, molecular targeted medicine has been used to treat non-small cell lung cancer (NSCLC) patients and proved to be significantly effective. Anaplastic lymphoma kinase (ALK) inhibitor is one of the most important specific therapeutic agents for patients with ALK-positive NSCLC. It can extend the survival of patients. However, resistance to the ALK inhibitor inevitably develops in the application process. So, the real-time resistance surveillance is particularly important, and liquid biopsy is one of the most potential inspection methods. Circulating tumor cells, circulating free tumor DNA and exosome in body fluid are used as the main detection biomarkers to reflect the occurrence of resistance in real time through sequencing or counting and then to guide the follow-up treatment. Keywords: NSCLC, ALK, resistance, liquid biopsy, CTCs, ctDNA, exosome